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Background: SARS-CoV-2 has challenged health service provision worldwide. This work evaluates safe surgi-
cal pathways and standard operating procedures implemented in the high volume, global city of London dur-
ing the first wave of SARS-CoV-2 infection. We also assess the safety of minimally invasive surgery(MIS) for
anatomical lung resection.
Methods: This multicentre cohort study was conducted across all London thoracic surgical units, covering a
catchment area of approximately 14.8 Million. A Pan-London Collaborative was created for data sharing and
dissemination of protocols. All patients undergoing anatomical lung resection 1st March-1st June 2020 were
included. Primary outcomes were SARS-CoV-2 infection, access to minimally invasive surgery, post-operative
complication, length of intensive care and hospital stay (LOS), and death during follow up.
Findings: 352 patients underwent anatomical lung resection with a median age of 69 (IQR: 3586) years.
Self-isolation and pre-operative screening were implemented following the UK national lockdown. Pre-oper-
ative SARS-CoV-2 swabs were performed in 63.1% and CT imaging in 54.8%. 61.7% of cases were performed
minimally invasively (MIS), compared to 59.9% pre pandemic. Median LOS was 6 days with a 30-day survival
of 98.3% (comparable to a median LOS of 6 days and 30-day survival of 98.4% pre-pandemic). Significant com-
plications developed in 7.3% of patients (Clavien-Dindo Grade 34) and 12 there were re-admissions(3.4%).
Seven patients(2.0%) were diagnosed with SARS-CoV-2 infection, two of whom died (28.5%).
Interpretation: SARS-CoV-2 infection significantly increases morbidity and mortality in patients undergoing
elective anatomical pulmonary resection. However, surgery can be safely undertaken via open and MIS
approaches at the peak of a viral pandemic if precautionary measures are implemented. High volume
surgery should continue during further viral peaks to minimise health service burden and potential
harm to cancer patients.
Funding: This work did not receive funding.
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Research in context
Evidence before this study
The SARS-CoV-2 pandemic has had a huge impact on surgical
specialties across the UK, with significant reductions in elective
surgical volume. The rationale for this is multifaceted, however
includes lack of intensive care provision, redeployment of staff,
repurposing of theatre space, risk of viral spread during aerosol
generating procedures, and a fear of increased morbidity and
mortality associated with SARS-CoV-2 infection in the perioper-
ative period. Data surrounding the impact of SARS-CoV-2 on
radically treatable lung cancer patients remains conflicting,
with only 2 cohort studies focusing on safe elective operating
during a period of low population incidence of viral infection.
We report the experience of the London Collaborative through-
out the first wave of the pandemic during the peak of infection
and resource limitation.
Added value of this study
Our data demonstrate that safe elective thoracic surgery can be
maintained during viral pandemic peaks in areas of high SARS-
CoV-2 infection provided strict screening and isolation proto-
cols are maintained. Furthermore, minimal access surgery
(both thoracoscopic and robotic assisted) remains safe and
should be continued where possible.
Implication of all the available evidence
We provide a framework for elective operating during the pan-
demic through qualitative descriptions of experience and con-
sensus opinion across a global city. Many surgical units have
struggled to maintain elective case volume, whilst oncologists
have emphasised the impact of treatment delay on both stage
migration and survival. This data highlights the need for collab-
oration to optimise treatment pathways, learning from the
experiences of other regional centres to provide evidence
based, safe, and timely radical surgery for lung cancer.
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In December 2019, an outbreak of atypical pneumonia was first
reported in Wuhan, China. A novel respiratory coronavirus, named
SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2) [1]
spread globally and as of the May 2021 there have been more than
173 million confirmed cases of SARS-CoV-2 infection including more
than 3.7 million deaths [2].
Within London, the first case of SARS-CoV-2 infection was con-
firmed on the 11th of February 2020 and there have subsequently
been 721, 953 confirmed cases with 19, 083 deaths with SARS-CoV-2
on the death certificate in a population of almost 9 million. On the
23rd of March, the UK government imposed a national lockdown. At
the peak of the first wave on the 2nd of April, more than 5000 hospi-
tal beds were occupied by patients with confirmed SARS-CoV-2 infec-
tion representing nearly a quarter of all inpatient bed capacity. At this
peak, there were 1073 new confirmed cases within a single 24-h
period [3]. In response to the increasing demand for intensive care
(ITU) beds, unprecedented measures were implemented including
the deferral of thousands of non-urgent operations, the use of private
hospitals by NHS patients and the creation of new sites such as the
Nightingale Hospital.
In the aftermath of these changes, many cancer clinicians have
considered the ramifications of delaying or deferring cancer care.Some estimates are alarming, with current estimates of thousands of
additional cancer-related deaths and tens of thousands of years of life
lost [4]. The reasons for deferral are logical, both chemotherapy and
surgery have demonstrable immunosuppressive effects and some
hypothesised that radiation pneumonitis could potentially increase
the severity of SARS-CoV-2 infection. However, more recently data
has begun to emerge that cancer therapy including chemotherapy
can continue without a significant increase in adverse effects during
the pandemic [5]. From a surgical perspective, initial research from
China demonstrated a 20% mortality rate in patients undergoing sur-
gery who developed SARS-CoV-2 infection [6]. More recent data from
Dublin, however, suggested that lung resection could proceed with
appropriate safety measures [7].
In order to provide a forum for the dissemination of data regard-
ing lung cancer patients in the high volume setting of a global city,
we created a collaborative group including all thoracic surgical
centres in London. We aimed to investigate the outcomes of anatomi-
cal lung resection in a general population with high rates of SARS-
CoV-2 infection, better guiding future oncological decision making
and demonstrating whether it is possible to safely maintain high sur-
gical volumes despite the current obstacles to care.
2. Methods
The Pan-London Thoracic Collaborative was set up in June 2020 in
response to the SARS-CoV-2 pandemic. All thoracic surgical centres
across London agreed to participate in the initiative. The referral base
for these centres expands across Southern English Counties encom-
passing an estimated overall population of 14.8 million and account-
ing for approximately 22% of the entire UK population (Fig. 1) [8].
Institutional approval was obtained from all Trusts contributing to
the collaborative. Approval was granted by each hospital trust for
data sharing, collaborative work and retrospective review. Formal
individual informed consent was not required due to the retrospec-
tive nature of the study.
The inclusion criterion for this study was all anatomical lung
resections performed between 1st March and 1st June 2020 (inclu-
sive). Non-anatomical lung resections and other thoracic surgical
procedures were excluded. There was no age restriction. Demo-
graphic, clinical and survival data for those patients who fulfilled the
inclusion criteria were collected retrospectively from review of case
records. The primary outcome was death during follow up. Secondary
outcomes were post-operative complications by Clavien-Dindo clas-
sification and diagnosis of SARS-CoV-2 infection. Referring units
were also required to submit information on the type and timing of
SARS-CoV-2 protocols within their institution including any screen-
ing methodology put in place and any other strategies to mitigate
SARS- CoV-2 infection risk. Analysis was performed on an intention
to treat basis meaning that although the majority of patients had a
confirmed cancer diagnosis, suspected cancers found to be benign or
metastatic on final pathology were included in the results.
Data was collected from all 7 London Thoracic Surgical Units. Sur-
gery was performed at a total of 9 hospital sites, owing to the devel-
opment of ‘COVID free’ beds at nearby hospitals. The practice of pre-
operative screening and isolation of patients was implemented in
line with trust protocols on each site with no change to standard
operating procedures occurring prior to 26th March 2020. Self-isola-
tion was not mandatory at all units, however, in some units patients
that chose to self-isolate were placed on a ‘Green’ protected pathway.
This pathway was defined as admission only to areas of the hospital
where all other patients had completed self-isolation and had a nega-
tive screening swab prior to admission. Other institutions were able
to admit all patients to side rooms until pre-operative swab results
were available. A summary of these protocols is shown in Table 1.
Continuous variables were assessed for normality using Shapiro-
Wilk testing. Non normally distributed variables were expressed as
Fig. 1. Catchment area of London Thoracic Surgical Centres. Dark grey area denotes regions covered by the pan London collaborative.
Table 1
SARS-CoV-2 specific admission and isolation protocols.
Site Admission Isolation Screening
Guy’s and St Thomas’ Hospital No elective operating after 28/03/20
Prior to 28/03/20 Standard admission and operating procedures with no SARS-CoV-2 specific screening
Hammersmith Hospital No elective operating after 31/03/20
Prior to 31/03/20 Standard admission and operating procedures with no SARS-CoV-2 specific screening
Harefield Hospital 48 h pre-operatively
Date Implemented: 26/03/20
14 days pre-operatively, strict self-isolation
Date implemented: 26/03/20
CT and nasopharangeal swab 48 h pre-opera-
tively
Date Implemented: 26/03/20
London Bridge Hospital 24 h pre-operatively (48 hrs at weekends)
Date implemented: 28/03/20
14 days pre-operatively, strict self-isolation
Date implemented: 28/03/20
Naso-pharyngeal swab on admission
Date implemented: 28/03/20
Royal Brompton Hospital
No elective operating after 26/03/20
Prior to 26/03/20 Standard admission and operating procedures with no SARS-CoV-2 specific screening
Royal Marsden Hospital 24 h pre-operatively (48 h at weekends)
Date implemented: 26/03/20
14 days pre-operatively, strict self-isolation
Date implemented: 26/03/20
Naso-pharyngeal swab and chest CT on
admission
Date implemented: 26/03/20
St Bartholomew’s Hospital 48 h pre-operatively
Date implemented: 26/03/20
Advised 14 days pre-operative self-isolation
although not mandatory
Date implemented: 26/03/20
Nose/throat swab on admission, trachea-
bronchial swab in theatre, side room until
results of deep swab available
Date implemented: 26/03/20
St George’s Hospital Patients could be admitted on day of surgery
or 24 h prior as per clinical requirement
Unchanged from usual clinical practice
Non-mandatory pre-operative isolation,
patients who chose to isolate were placed
in protected pathway,
Date implemented: 04/05/20






No pre-operative isolation Nose/throat swab on admission, side room
until results of deep swab available
Date implemented: 26/03/20
S. Fraser et al. / EClinicalMedicine 39 (2021) 101085 3median and interquartile range (IQR), normally distributed variables
expressed as mean § standard deviation. Categorical data were
expressed as counts and percentages. Univariable logistic analysis
was performed to explore whether any patient and procedure-
related factors were associated with higher risk of any complication
and death in our cohort. Statistical significance was defined where
p<0.05. All analysis was carried out using STATA version 12.0 (Leanne
Harling, Imperial College London).2.1. Role of funding source
This work received no specific funding.
3. Results
TaggedP he breakdown of cases performed at each site is shown in Table 2.
A total of 352 anatomical lung resections were performed during the
Table 2
Numbers of cases at each operative site.
Site 1stMarch-1stJune 2020 1stMarch-1stJune 2019
n % N %
Guy’s and St Thomas’
Hospital
42 11.9 160 30.7
Hammersmith Hospital 6 1.7 46 8.8
Harefield Hospital 29 8.2 75 14.4
London Bridge Hospital 74 21.0 0 0
Royal Brompton Hospital 4 1.1 58 11.1
Royal Marsden Hospital 39 11.1 0 0
St Bartholomew’s Hospital 73 20.7 65 12.5
St George’s Hospital 27 7.7 44 8.4
University College London
Hospital (UCLH)
58 16.5 73 14.0
TOTAL 352 521
4 S. Fraser et al. / EClinicalMedicine 39 (2021) 101085study period. This compares favourably to the 521 cases performed
during the same three months in 2019 (Table 2). The breakdown of
resection types is shown in Table 3. Initial concerns regarding the
role of minimally invasive surgery (MIS) during the pandemic [9]
relating to CO2 insufflation used for robotic procedures led to an early
move towards open surgery (Fig. 2a). However, on consultation with
virology teams, our SOP was quickly adapted to reflect the fact that
MIS lung resection in the thorax can be performed without excessive
aerosolization. As such, the majority of cases were performed via
video-assisted thoracoscopic surgery (VATS; 45.5%), with 38.4% beingTable 3
Patient and procedural demographics.









Current Smoker 171 (38.9%)
Ethnicity (n = 223)
White Caucasian 208 (93.3%)
Hypertension (n = 350) 133 (38.0%)
Diabetes mellitus (n = 350) 50 (14.3%)
Ischaemic heart disease 32 (9.0%)
Chronic kidney disease 9 (2.6%)
Cerebrovascular disease (n = 350) 29 (8.3%)
COPD (n = 346) 94 (27.2%)














Primary Lung Cancer 307 (87.5%)








Fig. 2. (a) Lung resections by surgical approach; (b) SARS-CoV-2 cases. (VATS: Video
Assisted Thoracic Surgery; RATS: Robotic Assisted Thoracic Surgery).performed via an open thoracotomy and 16.2% robotic-assisted thor-
acoscopic surgery (RATS)(Table 3). Notably, the proportion of patients
undergoing MIS reduced during the peak of the pandemic in London
(between late March and mid-April) (Fig. 2). However the number of
MIS procedures remained overall comparable to our baseline dataset
taken from the most recent UK Lung Cancer Clinical Outcomes Publi-
cation (LCCOP) validated dataset of the same institutions (Table 4).
The remainder of patient characteristics are shown in Table 3. 109
(31%) patients received no pre-operative screening for SARS-Cov2
(either swab or CT imaging). Notably all of these patients underwent
surgery before 14th April 2020 when availability of PCR testing was
extremely limited. 160 patients had CT imaging pre-operatively to
assess for the presence of pulmonary infiltrates. 6 patients received
pre-operative chemotherapy. There were 14 conversions from MIS to
open approaches, all of which were controlled.
Table 5 displays the outcomes after surgery. 101 (28.6%) patients
went to ICU post operatively, for a median of 1 day (IQR: 18). The
rate of ICU admission was higher than pre-pandemic where only
7.6%* of patients were admitted to ICU (*compared to a representa-
tive sample of 158 patients undergoing lung resection 1st March to
1st June 2018). This largely reflects the standard operating proce-
dures of the private hospitals which were free of any SARS-CoV-2
infection and where ICUs served as overnight recovery. 9/352 (2.6%)
patients received non-invasive ventilation and 3/352 (0.8%) patients
required invasive ventilation post operatively. Overall hospital stay
was a median of 6 days (IQR: 233), with length of stay from opera-
tion to discharge a median of 4 days (IQR: 126). Patients were fol-
lowed up for a median of 328 days (IQR: 299351). Complications
were seen in 162/352 (45.7%) patients. 130/352 (36.9%) were Clav-
ien-Dindo grade 12 comprising of hospital acquired chest infection
(HAP), post-operative atrial fibrillation (POAF), and prolonged air
leak (or a combination of these). More severe complications (Clavien-
Dindo grade 34) occurred in 26/352 (7.3%) patients. Return to the-
atre occurred in 12/352 (3.4%) patients and included 6 cases of bleed-
ing, 3 bronchoscopy and bronchial toilet, 2 surgical repair of
Table 4








Lobectomy/Bilobectomy/sleeve 277 (78.7%) 1399 (76%)
Segmentectomy/Sublobar 67 (19.0%) 330 (18%)
Pneumonectomy 2 (0.6%) 40 (2.2%)
Lung resection + chest wall 4 (1.1%) 37 (2.0%)
Approach
Open 135 (38.4%) 724 (40.0%)
VATS 160 (45.4%) 988 (54.6%)
RATS 57 (16.2%) 97 (5.3%)
Outcomes
Length of Stay (Median(IQR)) 6 (233) 6 (49)
30-day Survival 98.3% 98.4%
Results reported as n(%) or Median(IQR).
Table 5




















S. Fraser et al. / EClinicalMedicine 39 (2021) 101085 5bronchopleural fistulae and 1 return to theatre for completion lobec-
tomy (due to infection). The remainder of severe complications were
treated supportively on the ICU with renal replacement (n = 3), vaso-
pressor support (n = 3), and antibiotic treatment of severe chest sep-
sis requiring NIV (n = 9). There were 12/352 (3.4%) readmissions
following discharge, at a median of 11(813) days. Five of these were
due to persistent air leak or pneumothorax. Death during follow up
occurred in 6/352 (1.7%) patients at a median of 19 days (IQR: 524)
following surgery. Supplementary Table 1 displays the characteristics
of patients who died. Cause of death was respiratory failureTable 6
Characteristics and outcome in Patients with SARS-COV-2 infection.
Patient 1 Patient 2
Age 61 81
Sex M M
BMI (kg/m2) 25.0 27.4
Smoking (Ex; Non; Current) Non Ex




































Pre-operative CT No No
SARS-COV-2 infection




































WC: White Caucasian; EX: Ex-smoker; Non: Non-Smoker.
VATS: Video-assisted thoracoscopic surgery; RATS: Robotic-assisted t
Lobect: Lobectomy/Bilobectomy; Segem: Segmentectomy.
Cw: chest wall.secondary to SARS-CoV-2 in 2 cases, in the remaining 4 cases cause of
death was arrhythmia, self-harm, and pulmonary embolus. In one
case death occurred at home without defined cause. Notably, length
of stay and overall survival remained comparable to baseline data
(Table 4).
Seven (2.0%) patients were diagnosed as positive for SARS-COV-2
at a median of 4 days post operatively (428) (Table 6). Notably, one
patient tested positive pre-operatively and had surgery delayed for 4
weeks until clinically well and a negative swab result was confirmed.
Of the remaining 6 post-operative SARS-COV-2 positive cases, only
one was diagnosed after implementation of SARS-COV-2 specific
admission, isolation and screening protocols. Two patients died dur-
ing the post-operative period, both were diagnosed with coronavirusPatient 3 Patient 4 Patient 5 Patient 6 Patient 7
65 70 82 79 75
M M F F F
30.6 31.2 20.3 37.0 24.4
Ex Ex Non Ex Ex

















































































































6 S. Fraser et al. / EClinicalMedicine 39 (2021) 101085disease post operatively. The first death (Patient 1) was a white Cau-
casian 61-year-old male admitted electively for lung and rib resection
for a cT3N0 biopsy proven adenocarcinoma. His-only significant past
medical history was hypertension, his body mass index was 26.1.
His-operation occurred at the beginning of the pandemic in London,
prior to the implementation of lockdown measures. No pre-operative
swabbing for SARS-COV-2 infection or CT screening was performed.
His-recovery was initially uncomplicated however he became pyrex-
ial and tested positive for SARS-COV-2 infection on day 4 post-opera-
tively. He recovered sufficiently to be discharged on day 6 with some
ongoing pyrexia with advice from the local SARS-CoV-2 medical and
infection control teams. He was readmitted to his local hospital
intensive care unit 5 days after his discharge with multi-organ failure
and died on day 17 post-operatively.
The second death (Patient 2) was a white Caucasian 80-year-old
male whose initial pre-operative naso-pharyngeal swab was negative
for SARS-COV-2 infection. His-past medical history included hyper-
tension, diabetes mellitus, hypercholesterolaemia and prostate can-
cer. He underwent an open lobectomy for a pT2aN2 R0
adenocarcinoma which had a pre-operative staging of T2aN0M0 .
His-procedure was uncomplicated, however he developed early signs
of respiratory failure post-operatively and was managed in the high
dependency unit followed by ITU. Thorough clinical and radiological
investigation at this point was entirely consistent with SARS-CoV-2,
and despite a further negative swab multidisciplinary consensus
view was of SARS-CoV-2 infection. He was treated with non-invasive
ventilation and antiviral therapy however, continued to deteriorate
and died on day 4 post-operatively from respiratory failure.
Patient and procedure-related factors for any complication and
death were assessed via univariable logistic regression (Supplemen-
tary Table 2). As expected, male sex and higher risk surgical proce-
dures including sleeve lobectomy and chest wall resections when
compared to lobectomy were significant risk factors for ‘any’ compli-
cation and death, whilst hypertension, COPD and an open approach
were risk factors for ‘any’ complication.
Multivariable regression has been performed using 2 logistic
models. Model 1 included SARS-CoV-2 infection, age, gender BMI and
procedure type. Owing to collinearity between procedure type and
the use of minimal access approach, a second model was built utilis-
ing the latter variable. SARS-COV-2 infection remained the most sig-
nificant predictor of death in both models (Model 1: OR 17.2;
p = 0.008; Model 2: OR 20.1; p = 0.007) however procedure other
than lobectomy/segmentectomy was also associated with signifi-
cantly higher mortality in model 1 (OR 9.0; p = 0.043)(Supplementary
Table 3a). When examining the all complications outcome, male gen-
der, procedure other than lobectomy/segmentectomy (Model 1), and
open approach (Model 2), were associated with significantly higher
all cause complications (Supplementary Table 3b).
4. Discussion
This is the largest UK study to date of thoracic surgical patients
undergoing treatment during the coronavirus pandemic based in the
global city of London. We demonstrate the safety and tolerability of
anatomical lung resection during the initial peak with parity of access
to minimally-invasive surgery. Patients undergoing thoracic surgery
across London had similar morbidity and mortality rates as those
from the pre-SARS-CoV-2 era, the average length of stay was compa-
rable to previous data and re-admission rates were lower than previ-
ously reported [10].
We have demonstrated the importance of collaborative work dur-
ing periods of unprecedented change. The Pan-London Thoracic Col-
laborative provided a forum to discuss changes to standard operating
practice across NHS Trusts and helped units to rapidly adapt their
practice alongside evolving evidence. There was clear geographical
variation in the number of SARS-CoV-2 cases across London. Thecorresponding variation in activity between units partly reflects this
discrepancy, but was also influenced by factors such as the number of
ITU beds, the number of beds occupied by patients with SARS-COV-2
infection, the presence of a large infectious disease team, the avail-
ability of extra-corporeal membrane oxygenation and the availability
of a separate ‘clean’ site. These institutional differences highlight the
importance of pooling resources and offering surgeons honorary con-
tracts at other sites across London to reduce inequalities in cancer
care.
These data contribute to the ongoing discussion regarding optimal
timing of lung resection. Initial evidence in the coronavirus pandemic
supported the deferral or delay of surgery in ‘stable cancer’ [11].
Guidelines from the American College of Surgeons suggested a surgical
delay for tumours such as ground-glass nodules where survivorship
without radical treatment was felt to be possible with a three-month
deferral [12]. However, we propose that a delay in radical surgical
treatment for any early stage lung cancer, due to the fear of worse out-
come relating to SARS-CoV-2 infection, is not indicated if appropriate
measures are taken to protect patients during the peri-operative
period. The low incidence of severe (Clavien-Dindo grade 3+) morbid-
ity andmortality observed in our patient group suggests that operating
should continue at the current volume, even in the instance of a sec-
ond or subsequent wave of SARS-CoV-2 infections.
Our data support previous literature which highlighted the
increased risks of SARS-CoV-2 infection in lung cancer patients [13].
Of the seven patients who developed SARS-CoV-2 infection, there
was a 28.5% mortality rate (n = 2), compared to a 15% fatality rate in
the general populace of the UK [14]. Some research has suggested
that surgery could accelerate the disease process [6] while others
reported that patient-specific factors such as age and co-morbidity
were independent risk factors for poor outcome rather than cancer-
specific factors such as previous surgery [15]. Either way, measures
to reduce the risk of SARS-CoV-2 infection in patients awaiting cancer
treatment is clearly the goal for surgical teams.
It is our consensus opinion that surgical treatment should be
deferred when there is a SARS-CoV-2 diagnosis pre-operatively. We
have successfully operated on patients who tested positive on pre-
operative naso-pharyngeal swabbing after an interval period of one
month with no unanticipated morbidity or longer term sequalae. The
optimum timing of surgery following SARS-CoV-2 infection should
be decided in conjunction with local infection control and virology
teams, but at least a four week delay is supported by international
data from the COVIDSurg Collaborative [16].
During the study period, advice was implemented in England
which suggested a 14-day period of mandatory self-isolation and
SARS-CoV-2 naso-pharyngeal swabbing within 72 h for all asymp-
tomatic patients undergoing elective surgery [17]. From our data, the
implementation of mandatory self-isolation had a significant positive
impact on patient outcomes, with no cases of coronavirus identified
during the in-patient stay after this was in effect.
Recent NICE guidance has suggested a move towards eleven days
of social-distancing and careful hand hygiene, with strict isolation for
only three days prior to surgery [18]. However, in our experience of
the second wave this led to outbreaks of SARS-CoV-2 infection and
we continue to advocate a 14-day mandatory self-isolation period
during the peak of a pandemic when community rates of infection
are high. We also advocate that patients are encouraged to continue
shielding post-operatively during pandemic peaks. This relates to
recent literature which studied the higher rates of SARS-CoV-2 infec-
tion in patients with non-small cell lung cancer (NSCLC) and found
that surgery within the last month was a risk factor for severe mor-
bidity and mortality [19].
As per recent literature from the COVIDSURG Collaborative, pre-
operative nose and throat PCR swabbing is effective in reducing pul-
monary complications associated with major surgery. Routine swab-
bing was introduced a third of the way through our study period
S. Fraser et al. / EClinicalMedicine 39 (2021) 101085 7across London and therefore early patients who developed SARS-
CoV-2 infection were not screened. The low volume of SARS-CoV-2
infection in our population despite the high rates of infection in Lon-
don during this time reflect the robustness of pre-operative swabbing
and it is our group consensus that this would be an ideal SOP for
maintaining safe surgery [20]. Our data also however re-emphasises
the fact that false negative results from pre-operative nose and throat
SARS-CoV-2 RT-PCR swabbing can occur [21]. The impact of inaccu-
rate swabbing is highlighted in the case we present of a patient with
a clinical and radiological diagnosis of SARS-CoV-2 but negative pre-
and post-operative coronavirus swab results, who ultimately died as
a result of his SARS-CoV-2 infection in the early post-operative
period. Following our move back to NHS hospitals with ‘protected’
and ‘non-protected’ pathways and fewer side rooms, it was essential
that the sensitivity of swabbing was assessed and that an effective
self-swabbing protocols were implemented to improve safety for
both patients and healthcare professionals.
A published consensus opinion of individuals involved in manag-
ing thoracic malignancies supported the use of pre-operative CT
screening for SARS-CoV-2 [22]. At the onset of the pandemic, owing
to the limited testing capacity and initial concerns regarding the
accuracy of nose and throat PCR swabbing, CT screening was
utilised at several London Centres. This was not however supported
by subsequent research from the COVIDSurg Collaborative or the UK
consensus of the combined Royal Colleges and Associations of Sur-
geons [17,20]. Their data highlights the low sensitivity and specificity
of a pre-operative CT chest in diagnosing SARS-CoV-2 infection in
asymptomatic patients prior to elective surgery. They do not recom-
mend it as a suitable screening tool, but advise that it can be
employed in certain circumstances such as patients who are planned
to recover in HDU or ITU areas [23]. In practical terms, the need for
admission 1.52 days prior to surgery for naso-pharnygeal swabbing
followed by CT scanning and then reporting, limited the use of this
protocol, particularly when beds were in short supply. From our data
however, the lack of pre-operative CT screening was an independent
risk factor for SARS-CoV-2 infection.
The results of this study should be considered in the context of a
number of limitations. First, we appreciate at present there is a lack
of long-term follow up to determine the sequelae of SARS-CoV-2
infection in thoracic surgical patients. Second, clinical stage data
were limited, resulting in difficulties commenting on stage progres-
sion. This is in part due to the impact of the pandemic on aerosol gen-
erating procedures such as endobronchial ultrasound (EBUS), which
were completely suspended in a number of peripheral referral
centres. It is therefore essential that we continue to study the onco-
logical outcomes of patients treated during the coronavirus pandemic
and strive to overcome these limitations for future waves. Many cur-
rent oncology models suggest that priority setting could result in
either delays in treatment, or the decision not to proceed with adju-
vant chemotherapy for NSCLC following surgery [24]. Within our
own cohort, at least one patient did not receive adjuvant treatment
following a referral to oncology due to the coronavirus pandemic.
The patient was found to have disease progression at 3-month sur-
veillance imaging, which was subsequently proven histologically.
Whilst we appreciate surgical intervention itself confers risks of
major morbidity and mortality, the overall mortality from surgery
remains low in comparison to the reduction in survival in patients
receiving delayed or no treatment [25].
As part of shared decision making, all patients with early stage
disease were counselled regarding their options for radical treatment
including surgery and sterotactic radiotherapy (SBRT). There is also
evidence for upfront SBRT followed by a salvage lobectomy to avoid
the peri-operative risks of SARS-CoV-2 infection [26]. However, it
was our experience at the initial peak of the pandemic that access to
SBRT was more limited than usual, in part due to concerns regarding
viral pneumonitis. All options should be discussed with patients aspart of routine counselling with the aim of ensuring radical treatment
for the largest proportion of early stage lung cancer patients.
We also must consider bias such as low re-admission rates reflect-
ing the inability of patients to safely access primary care or local hos-
pital follow up rather than a true improvement in outcomes. Current
rates of 90-day re-admission in the UK following lung resection are
approximately 41% [10], but with reduced access to general practi-
tioners (GPs) and district nurses, post-operative complications such
as pain and respiratory tract infections may not be identified or
appropriately managed.
The route by which new diagnoses of lung cancer present must
also be considered as we move forward. Prior to the coronavirus pan-
demic, around 41% of new diagnoses of lung cancer were made fol-
lowing a GP referral. During the coronavirus pandemic, the overlap of
respiratory symptoms relating to lung cancer and SARS-CoV-2 infec-
tion resulted in many patients in the UK being advised to self-isolate
rather than present to their GP [27]. This is consistent with data
which demonstrated up to an 80% reduction in urgent referrals for
suspected cancer [4]. This is echoed in other oncology work which
demonstrated that a two-month delay in urgent referral for investi-
gation results in up to 0.7 life-years lost per patient and that young
cancer patients were disproportionately affected by delays to their
care [28]. We must consider ways of identifying this cohort of
patients. Although some recent literature suggested that lung cancer
screening and nodule follow up should be deferred [29], the benefits
and risks of wider enrolment in lung cancer CT screening pro-
grammes should be considered as a means of reducing this inequality
in cancer care.
SARS-CoV-2 infection results in significantly increased morbidity
and mortality in patients undergoing elective anatomical pulmonary
resection for primary lung cancer. However, elective anatomical pul-
monary resection for primary lung cancer surgical resection remains
feasible and safe during pandemic peaks provided strict admission,
isolation and testing protocols are implemented. Treatment path-
ways should be maintained and unnecessary delays to treatment
avoided, so as to prevent the unnecessary morbidity and mortality
associated with disease progression.
Early establishment of collaborative groups to guide surgical spe-
ciality-specific decision making is of paramount importance to ensure
rapid refinement of protocols and streamlining of care pathways. Fur-
thermore, such collaborations facilitate the development of reporting
systems and learning from a larger evidence base in the event of a
rapidly evolving pandemic situation.Authors’ contributions
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